Cromagnon, instead just to criticise, we would be more...

Cromagnon, instead just to criticise, we would be more supportive in providing current management with the proposals and tools to win in our mission to bring VitroGro® to the market.
We all know that there are difficulties, and we all know that many times these processes are fundamental to learn and build a better team (I prefer to not be the case, but the facts have taken us here).
The Board has decided to look for a new CEO. It could be a fantastic boost, as a good and capable name could drive foreign interests to Tissue Therapies.
We have some hard issues such as the Regulatory approval process, but on the other side we have a good product that works.
If you look at the US market, it is full of biotech companies that even with a product that has not been tested (Phase 1 and 2 trials), they are valued at least USD 150,000,000-300,000,000.
In comparison it would be the A$1 valuation (300,000,000 shares at A$1) that we have been looking to reach from such a long time.

True is that in 4-5 years the number of shares issued by the management have been doubled. We have got a 50% dilution.
The financing process in this way has to be stopped. It is much more convenient to involve a partner on a future earning sharing contract and that support and finance the US clinical trials.

We have an opportunity, and we are at the right moment to position properly the company in a way to be satisfactory for the shareholders.

How would react the market with a CEO onboard that previously was a Johnson's & Johnson's Director?
How would react the market if Sanofi would like to finance VitroGro® US clinical trial process?

PARTNERSHIP is a must. We have to build a Bridge. Tissue must be a GLOBAL company and need to eradicate its Australian roots. There is VALUE, but the market does not yet see it?
Why?
COMUNICATION on a GLOBAL perspective.